Stock Analysis
- United Kingdom
- /
- Pharma
- /
- AIM:CEL
Celadon Pharmaceuticals First Half 2023 Earnings: UK£0.07 loss per share (vs UK£0.25 loss in 1H 2022)
Celadon Pharmaceuticals (LON:CEL) First Half 2023 Results
Key Financial Results
- Net loss: UK£4.30m (loss narrowed by 68% from 1H 2022).
- UK£0.07 loss per share (improved from UK£0.25 loss in 1H 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Celadon Pharmaceuticals shares are down 10% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Celadon Pharmaceuticals (3 are a bit concerning!) that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Celadon Pharmaceuticals is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:CEL
Celadon Pharmaceuticals
Engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines.
Medium-low with imperfect balance sheet.